

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5490924

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	PATENT SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
THERAPEUTICSMD, INC.	04/24/2019

RECEIVING PARTY DATA

Name:	TPG SPECIALTY LENDING, INC.
Street Address:	888 7TH AVENUE, 35TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10106

PROPERTY NUMBERS Total: 70

Property Type	Number
Patent Number:	8577716
Patent Number:	8633178
Patent Number:	8846648
Patent Number:	8846649
Patent Number:	8933059
Patent Number:	8987237
Patent Number:	8987238
Patent Number:	8993548
Patent Number:	8993549
Patent Number:	9006222
Patent Number:	9012434
Patent Number:	9114145
Patent Number:	9114146
Patent Number:	9180091
Patent Number:	9248136
Patent Number:	9289382
Patent Number:	9296780
Patent Number:	9301920
Patent Number:	D801518
Patent Number:	9931349

PATENT

Property Type	Number
Patent Number:	10052386
Patent Number:	10098894
Patent Number:	10206932
Patent Number:	10258630
Application Number:	16104101
Application Number:	15090493
Application Number:	15999040
Application Number:	14512046
Application Number:	15832757
PCT Number:	US2017064788
Application Number:	15832750
Application Number:	16244020
Application Number:	16355532
Application Number:	62822609
Application Number:	14649818
Application Number:	14521230
Application Number:	14521002
Application Number:	15372385
Application Number:	62680715
Application Number:	15893542
Application Number:	15893550
Application Number:	15975733
Application Number:	15975723
Application Number:	15781840
Application Number:	16004338
Application Number:	16006721
Application Number:	16037452
Application Number:	15454898
Application Number:	16273955
Application Number:	16125201
Application Number:	15420019
Application Number:	16167294
Application Number:	16283624
Application Number:	15840399
Application Number:	15217301
Application Number:	13843362
Application Number:	15475052
PCT Number:	US2017025211

Property Type	Number
PCT Number:	US2017025220
Application Number:	15473742
Application Number:	16359839
PCT Number:	US2017024955
Application Number:	15901467
PCT Number:	US2017024994
Application Number:	62742234
Application Number:	62742210
Application Number:	62742168
Application Number:	62742173
Application Number:	16265222
Application Number:	15475068

CORRESPONDENCE DATA

Fax Number: (212)593-5955
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Phone: (212) 756-2132
Email: scott.kareff@srz.com
Correspondent Name: SCOTT KAREFF
Address Line 1: SCHULTE ROTH & ZABEL, 919 THIRD AVE
Address Line 4: NEW YORK, NEW YORK 10022

ATTORNEY DOCKET NUMBER:	079464.0135
NAME OF SUBMITTER:	SCOTT KAREFF
SIGNATURE:	/RS for SK/
DATE SIGNED:	04/24/2019

Total Attachments: 15
source=TherapeuticsMD - Patent Security Agreement#page1.tif
source=TherapeuticsMD - Patent Security Agreement#page2.tif
source=TherapeuticsMD - Patent Security Agreement#page3.tif
source=TherapeuticsMD - Patent Security Agreement#page4.tif
source=TherapeuticsMD - Patent Security Agreement#page5.tif
source=TherapeuticsMD - Patent Security Agreement#page6.tif
source=TherapeuticsMD - Patent Security Agreement#page7.tif
source=TherapeuticsMD - Patent Security Agreement#page8.tif
source=TherapeuticsMD - Patent Security Agreement#page9.tif
source=TherapeuticsMD - Patent Security Agreement#page10.tif
source=TherapeuticsMD - Patent Security Agreement#page11.tif
source=TherapeuticsMD - Patent Security Agreement#page12.tif
source=TherapeuticsMD - Patent Security Agreement#page13.tif
source=TherapeuticsMD - Patent Security Agreement#page14.tif
source=TherapeuticsMD - Patent Security Agreement#page15.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "**Agreement**"), dated as of April 24, 2019, is entered into by and among TherapeuticsMD, Inc., a Nevada corporation (the "**Grantor**") and TPG Specialty Lending, Inc. (the "**Assignee**"), as Administrative Agent pursuant to (i) that certain Pledge and Security Agreement, dated as of April 24, 2019, among the Assignee, the Grantor and the other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the "**Security Agreement**"), and (ii) that certain Financing Agreement, dated as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the "**Financing Agreement**"), between, among others, certain of the Grantor's affiliates, the Assignee, and certain Lenders party thereto.

Capitalized terms not otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as applicable.

WHEREAS, pursuant to the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the federally registered Patents set forth on Schedule A hereto as of the date hereof.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor and the Assignee hereby agree as follows:

1. Grant of Security Interest

(a) Subject to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor's right, title and interest in, to and under the Patents, whether now owned or existing or at any time hereafter acquired or arising and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Grantor's Secured Obligations. For the purposes of this Agreement, "Patents" means (i) all letters patent of the United States, all reissues and extensions thereof and all goodwill associated therewith, including, without limitation, any of the foregoing referred to on Schedule A hereto, (ii) all applications for letters patent of the United States, continuations and continuations-in-part thereof, including, without limitation, any of the foregoing referred to on Schedule A hereto, and (iii) all rights to obtain any reissues or extensions of the foregoing.

(b) Schedule A hereto contains a true and accurate list of all of the Grantor's federally registered United States registrations and applications for registration for the Patents existing as of the date hereof.

(c) The security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

2. Modifications

This Agreement or any provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement without obtaining the Grantor's signature to such modification, to the extent that such modification constitutes an

amendment of Schedule A hereto, to add any right, title or interest in any Patents owned or subsequently acquired by the Grantor or to delete any reference to any right, title or interest in any Patents in which the Grantor no longer has or claims any right, title or interest. The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any Patent to the security interests and perfection created or contemplated hereby or by the Security Agreement.

3. Applicable Law

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

4. Counterparts

This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and all of said counterparts taken together shall be deemed to constitute one and the same instrument.

[Signature pages to follow]

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.


ASSIGNEE:

TPG SPECIALTY LENDING, INC.

By: _____

Name:

Title:



JOSHUA EAKERY
CEO

Address of Assignee:
888 7th Avenue, 35th Floor
New York, NY 10106

GRANTOR:

THERAPEUTICSMD, INC.

By:

A handwritten signature in black ink, appearing to read 'Daniel Cartwright', is written over a horizontal line. The signature is stylized and cursive.

Name: Daniel Cartwright

Title: Chief Financial Officer and Treasurer

Address of Grantor:

6600 Broken Sound Parkway NW, Suite 100
Boca Raton, FL 33487

[Patent Security Agreement]

PATENT
REEL: 048990 FRAME: 0826

Schedule A¹²

Issued Patents:

	Patent Number	Title	Filing Date (mm/dd/yy)	Issue Date (mm/dd/yy)	Country
1.	8,577,716	System and Method of Ongoing Evaluation Reporting and Analysis	09/17/09	11/05/13	US
2.	8,633,178	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	01/21/14	US
3.	8,846,648	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	09/30/14	US
4.	8,846,649	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	09/30/14	US
5.	8,933,059	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	01/13/15	US
6.	8,987,237	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	03/24/15	US
7.	8,987,238	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	03/24/15	US
8.	8,993,548	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	03/31/15	US
9.	8,993,549	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	03/31/15	US
10.	9,006,222	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	04/14/15	US
11.	9,012,434	Natural Combination Hormone Replacement Formulations and Therapies	12/06/13	04/21/15	US
12.	9,114,145	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	08/25/15	US
13.	9,114,146	Natural Combination Hormone Replacement Formulations and Therapies	09/03/14	08/25/15	US
14.	9,180,091	Soluble Estradiol Capsule for Vaginal Insertion	12/20/13	10/10/15	US
15.	9,248,136	Transdermal Hormone Replacement Therapies	12/12/13	02/02/16	US
16.	9,289,382	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	02/17/15	03/22/16	US

¹ Grantor is the holder of all intellectual property unless otherwise indicated.

² Key: pink - Imvexxy, purple - Bijuva, blue – Annovera.

	Patent Number	Title	Filing Date (mm/dd/yy)	Issue Date (mm/dd/yy)	Country
17.	9,296,780*	Process for Alkynylating 16-Substituted-17-Keto Steroids	12/19/12	03/29/16	US
18.	9,301,920	Natural Combination Hormone Replacement Formulations and Therapies	03/15/13	04/05/16	US
19.	D801,518	Pharmaceutical Capsule	06/22/15	10/31/17	US
20.	9,931,349	Steroid Hormone Pharmaceutical Composition	03/30/17	04/03/18	US
21.	10,052,386	Progesterone Formulations	12/11/13	08/21/18	US
22.	10,098,894	Transdermal Cream	07/29/15	10/16/18	US
23.	10,206,932	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	02/19/19	US
24.	10,258,630	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	02/09/18	04/17/19	US
25.	89459	Pharmaceutical Capsule	12/22/15	02/17/16	AR
26.	366507	Pharmaceutical Capsule	12/21/15	01/12/16	AU
27.	2012340589	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	08/25/16	AU
28.	2013211876	Transdermal Hormone Replacement Therapies	01/25/13	05/25/17	AU
29.	2013277236	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	08/03/17	AU
30.	2013277234	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	08/10/17	AU
31.	MX 358440 B	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	08/03/18	MX
32.	166,044	Pharmaceutical Capsule	12/17/15	08/16/16	CA
33.	002916247-0001	Pharmaceutical Capsule	12/18/15	08/10/16	EP
34.	30201500585 9-5	Pharmaceutical Capsule	12/21/15	01/30/18	BR
35.	6285866	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	02/09/18	JP
36.	6298460	Progesterone Formulations	06/18/13	03/02/18	JP

* Licensed patent or patent application.

	Patent Number	Title	Filing Date (mm/dd/yy)	Issue Date (mm/dd/yy)	Country
37.	MX 50237 B	Pharmaceutical Capsule	12/18/15	07/19/17	MX
38.	30-2015-0065043	Pharmaceutical Capsule	12/18/15	03/06/17	KR
39.	101179	Pharmaceutical Capsule	12/21/15	01/10/17	RU
40.	A2015/01935	Pharmaceutical Capsule	12/21/15	05/16/17	ZA
41.	2015/00211	Natural Combination Hormone Replacement Therapies	06/18/13	07/27/16	ZA
42.	2015/00212	Progesterone Formulations	06/18/13	04/26/17	ZA
43.	6334519	Natural Combination Hormone Replacement Therapies	06/18/13	05/11/18	JP
44.	6342334	Transdermal Hormone Replacement Therapies	01/25/13	05/25/18	JP
45.	6342389	Transdermal Hormone Replacement Therapies	06/18/13	05/25/18	JP
46.	6397402	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	09/07/18	JP
47.	2013277235	Transdermal Hormone Replacement Therapies	06/18/13	08/02/18	AU
48.	2013277233	Progesterone Formulations	06/18/13	09/13/18	AU
49.	1624393	Pharmaceutical Capsule	12/21/15	01/18/19	JP
50.	2861234B	Progesterone Formulations	06/18/13	03/27/19	EP
51.	2806742B	Transdermal Hormone Replacement Therapies	01/25/13	03/27/19	EP

Pending Patent Applications:

	Application Number	Title	Application Date (mm/dd/yy)	Country
1.	16/104.101	Natural Combination Hormone Replacement Formulations and Therapies	08/16/18	US
2.	BR1120140124442	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	BR
3.	2.856.520	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	CA

	Application Number	Title	Application Date (mm/dd/yy)	Country
4.	12850845.4	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	EP
5.	2017-173842	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	JP
6.	MX/a/2014/006256	Natural Combination Hormone Replacement Formulations and Therapies	11/21/12	MX
7.	15/090,493	Natural Combination Hormone Replacement Formulations and Therapies	04/04/16	US
8.	20140101244	Natural Combination Hormone Replacement Formulations and Therapies	03/17/14	AR
9.	2017206262	Natural Combination Hormone Replacement Formulations and Therapies	07/20/17	AU
10.	BR1120140319103	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	BR
11.	2,876,977	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	CA
12.	13806855.6	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	EP
13.	236358	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	IL
14.	2017-176379	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	JP
15.	10-2015-7001189	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	KR
16.	MX/a/2014/015898	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	MX
17.	2015100533	Natural Combination Hormone Replacement Formulations and Therapies	06/18/13	RU
18.	15/999,040	Natural Combination Hormone Replacement Formulations and Therapies	08/16/18	US
19.	14/512,046	Natural Combination Hormone Replacement Formulations and Therapies	10/10/14	US
20.	20150101608	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	AR
21.	2015264003	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	AU

	Application Number	Title	Application Date (mm/dd/yy)	Country
22.	BR112016 027359.1	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	BR
23.	2,947,767	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	CA
24.	15727528.0	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	EP
25.	248985	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	IL
26.	2016-565647	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	JP
27.	10-2016-7032773	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	KR
28.	MX/a/2016/014281	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	MX
29.	2016143081	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	RU
30.	2016/07541	Natural Combination Hormone Replacement Formulations and Therapies	05/22/15	ZA
31.	15/832.757	Natural Combination Hormone Replacement Formulations and Therapies	12/05/17	US
32.	PCT/US2017/064788	Natural Combination Hormone Replacement Formulations and Therapies	12/05/17	PCT
33.	15/832.750	Natural Combination Hormone Replacement Formulations and Therapies	12/05/17	US
34.	16/244,020	Natural Combination Hormone Replacement Formulations and Therapies	01/09/19	US
35.	16/355,532	Natural Combination Hormone Replacement Formulations and Therapies	03/15/19	US
36.	62/822,609	Natural Combination Hormone Replacement Formulations and Therapies	03/22/19	US
37.	14/649,818	Soluble Estradiol Capsule for Vaginal Insertion	12/17/15	US
38.	2017208300	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	AU
39.	BR112014031 9146	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	BR
40.	2,876,968	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	CA
41.	13807188.1	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	EP

	Application Number	Title	Application Date (mm/dd/yy)	Country
42.	236359	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	IL
43.	10-2015-7001193	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	KR
44.	MX/A/2018/09466	Soluble Estradiol Capsule for Vaginal Insertion	08/02/18	MX
45.	2015100531	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	RU
46.	2014/09278	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	ZA
47.	2018-162966	Soluble Estradiol Capsule for Vaginal Insertion	06/18/13	JP
48.	14/521,230	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	US
49.	20140103975	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	AR
50.	2014349132	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	AU
51.	BR1120160090080	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	BR
52.	2,926,342	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	CA
53.	14862905.8	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	EP
54.	245139	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	IL
55.	2016-516086	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	JP
56.	10-2016-7010901	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	KR
57.	MX/A/2016/05092	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	MX
58.	2016118396	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	RU
59.	2016/01933	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	ZA
60.	14/521,002	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	10/22/14	US
61.	15/372,385	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	US

	Application Number	Title	Application Date (mm/dd/yy)	Country
62.	PCT/US2016/065466	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	PCT
63.	20160103768	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	AR
64.	2016366200	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	AU
65.	BR1120180114839	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	BR
66.	3,007,636	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	CA
67.	16873806.0	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	EP
68.	19122548.1	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	04/17/19	HK
69.	259884	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	IL
70.	2018-529574	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	JP
71.	10-2018-7019331	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	KR
72.	MX/A/2018/06882	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	MX
73.	743229	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	NZ
74.	2018121094	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	RU
75.	2018/03804	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	12/07/16	ZA
76.	62/680,715	Vaginal Inserted Estradiol Pharmaceutical Formulations and Methods	06/06/18	US
77.	15/893,542**	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	02/09/18	US
78.	15/893,550**	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	02/09/18	US

** Application contains allowable subject matter and a patent will issue in due course.

	Application Number	Title	Application Date (mm/dd/yy)	Country
79.	15/975,733	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	05/09/18	US
80.	15/975,723	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	05/09/18	US
81.	15/781,840	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/06/18	US
82.	16/004,338	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/08/18	US
83.	PCT/US2018/36790	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/08/18	PCT
84.	16/006,721	Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods	06/12/18	US
85.	16/037,452	Progesterone Formulations	07/17/18	US
86.	2018222947	Progesterone Formulations	06/18/13	AU
87.	BR1120140318379	Progesterone Formulations	06/18/13	BR
88.	2,876,964	Progesterone Formulations	06/18/13	CA
89.	MX/a/2014/015900	Progesterone Formulations	06/18/13	MX
90.	MX/a/2018/009467	Progesterone Formulations	08/02/18	MX
91.	15/454,898	Progesterone Formulations Having a Desirable PK Profile	03/09/17	US
92.	20150100920	Progesterone Compositions	03/27/15	AR
93.	2015237243	Progesterone Formulations	03/27/15	AU
94.	BR1120160225708	Progesterone Formulations	03/27/15	BR
95.	2,942,568	Progesterone Formulations	03/27/15	CA
96.	15768772.4	Progesterone Formulations	03/27/15	EP
97.	247828	Progesterone Formulations	03/27/15	IL
98.	2016-557059	Progesterone Formulations	03/24/15	JP
99.	10-2016-7029519	Progesterone Formulations	03/27/15	KR
100.	MX/A/2016/011706	Progesterone Formulations	03/27/15	MX
101.	2016136666	Progesterone Formulations	03/27/15	RU
102.	2016/06309	Progesterone Formulations	03/27/15	ZA

	Application Number	Title	Application Date (mm/dd/yy)	Country
103.	16/273,955	Progesterone Formulations Having a Desirable PK Profile	02/12/19	US
104.	16/125,201	Transdermal Cream	09/07/18	US
105.	P20150102431	Transdermal Cream	07/29/15	AR
106.	2015296609	Transdermal Cream	07/29/15	AU
107.	BR1120160293380	Transdermal Cream	07/29/15	BR
108.	2,951,284	Transdermal Cream	07/29/15	CA
109.	15827543.8	Transdermal Cream	07/29/15	EP
110.	248984	Transdermal Cream	07/29/15	IL
111.	2016-571728	Transdermal Cream	07/29/15	JP
112.	10-2017-7002451	Transdermal Cream	07/29/15	KR
113.	MX/a/2016/013693	Transdermal Cream	07/29/15	MX
114.	2016141135	Transdermal Cream	07/29/15	RU
115.	2016/07317	Transdermal Cream	07/29/15	ZA
116.	15/420,019	Transdermal Cream	01/30/17	US
117.	16/167,294	Vitamin Compositions	10/22/18	US
118.	16/283,624	Chewable Vitamin Compositions	02/22/19	US
119.	15/840,399	System and Method of Ongoing Evaluation Reporting and Analysis	12/13/17	US
120.	15/217,301	Formulations for Solubilizing Hormones	07/22/16	US
121.	BR1120140184399	Transdermal Hormone Replacement Therapies	01/25/13	BR
122.	2,861,346	Transdermal Hormone Replacement Therapies	01/25/13	CA
123.	MX/A/2014/09093	Transdermal Hormone Replacement Therapies	01/25/13	MX
124.	13/843,362	Transdermal Hormone Replacement Therapies	03/15/13	US
125.	1120140318247	Transdermal Hormone Replacement Therapies	06/18/13	BR
126.	2,876,947	Transdermal Hormone Replacement Therapies	06/18/13	CA
127.	13807463.8	Transdermal Hormone Replacement Therapies	06/18/13	EP

	Application Number	Title	Application Date (mm/dd/yy)	Country
128.	MX/A/2014/015897	Transdermal Hormone Replacement Therapies	06/18/13	MX
129.	2015/00210	Transdermal Hormone Replacement Therapies	06/18/13	ZA
130.	15/475,052	Steroid Hormone Pharmaceutical Composition	03/30/17	US
131.	PCT/US2017/025211	Steroid Hormone Pharmaceutical Composition	03/30/17	PCT
132.	20170100832	Steroid Hormone Pharmaceutical Composition	04/03/17	AR
133.	2017239679	Steroid Hormone Pharmaceutical Composition	03/30/17	AU
134.	BR1120180698776	Steroid Hormone Pharmaceutical Composition	03/30/17	BR
135.	3,019,375	Steroid Hormone Pharmaceutical Composition	03/30/17	CA
136.	17776724.1	Steroid Hormone Pharmaceutical Composition	03/30/17	EP
137.	261924	Steroid Hormone Pharmaceutical Composition	03/30/17	IL
138.	2018-550593	Steroid Hormone Pharmaceutical Composition	03/30/17	JP
139.	10-2018-7031666	Steroid Hormone Pharmaceutical Composition	03/30/17	KR
140.	MX/A/2018/011706	Steroid Hormone Pharmaceutical Composition	03/30/17	MX
141.	746686	Steroid Hormone Pharmaceutical Composition	03/30/17	NZ
142.	2018133921	Steroid Hormone Pharmaceutical Composition	03/30/17	RU
143.	2018/06413	Steroid Hormone Pharmaceutical Composition	03/30/17	ZA
144.	15/475,068	Steroid Hormone Pharmaceutical Composition in Medium Chain Oils	03/30/17	US
145.	20170100831	Steroid Hormone Compositions in Medium Chain Oils	04/03/17	AR
146.	PCT/US2017/025220	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	PCT
147.	15/473,742	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	US
148.	16/359,839	Steroid Hormone Compositions in Medium Chain Oils	03/20/19	US
149.	PCT/US2017/024955	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	PCT
150.	15/901,467	Steroid Hormone Compositions in Medium Chain Oils	02/21/18	US

	Application Number	Title	Application Date (mm/dd/yy)	Country
151.	20170100830	Steroid Hormone Compositions in Medium Chain Oils	04/03/17	AR
152.	2017239645	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	AU
153.	BR1120180701998	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	BR
154.	3,020,153	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	CA
155.	17776645.8	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	EP
156.	261930	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	IL
157.	2018-550564	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	JP
158.	10-2018-7031878	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	KR
159.	MX/A/2018/011705	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	MX
160.	746682	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	NZ
161.	2018133932	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	RU
162.	2018/06414	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	ZA
163.	PCT/US2017/024994	Steroid Hormone Compositions in Medium Chain Oils	03/30/17	PCT
164.	20170100829	Steroid Hormone Compositions in Medium Chain Oils	04/03/17	AR
165.	62/742,234	Steroid Hormone Pharmaceutical Composition	10/05/18	US
166.	62/742,210	Steroid Hormone Compositions in Medium Chain Oils	10/05/18	US
167.	62/742,168	Steroid Hormone Pharmaceutical Composition	10/05/18	US
168.	62/742,173	Steroid Hormone Compositions in Medium Chain Oils	10/05/18	US
169.	16/265,222*	Method of Providing Birth Control	02/01/19	US